Majority shareholder family long-term committed to sustainable growth.
First 50 years history for CHF 500 million, next 5 year target for second CHF 500 million sales.
TIDES markets are facing disruptive changes, driven through medical needs with blockbuster potential and growing switch from recombinant to chemical peptides production.
Bachem is able to capture these opportunities across of CDMO capabilities through massive capacity investments and long-term partnerships with key players.
5
Bachem Capital Markets Day Sep 20, 2022
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bachem Holding AG published this content on 20 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 September 2022 06:09:06 UTC.
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
BACHEM HOLDING AG 
